Frequently Asked Questions for enhancing the utility and usage of Common Fund data sets
3. Where can I find more information about previously funded studies through the Notice of Special Interest: Availability of Administrative Supplements for Enhancing Utility and Usage of Common Fund Data sets?
- Conducting pilot or feasibility studies based on analyses across Common Fund data sets
- Building synthetic cohorts, combining and comparing data sets
- Developing research methods or analytic tools to support data visualization, harmonization, and integration
- Curating and/or annotating genomic information in the data sets
- Collecting additional phenotypic or clinical data to enhance data sets
- 4DNucleome: Reference nucleomics and imaging data sets, including an expanding tool set for open data processing and visualization
- Genotype-Tissue Expression (GTEx): Whole genome- and RNA sequence data from multiple human tissues to study tissue-specific gene expression and regulation, including tissue samples
- Illuminating the Druggable Genome (PHAROS):Data on understudied druggable proteins, including mRNA and protein expression data, phenotype associations, bioactivity data, drug target interactions, disease links, and functional information
- Integrated Human Microbiome Project: Microbiome, epigenomic, metabolomic, and phenotypic data for 3 cohorts
- Kinds First (KF DRC): Data from whole-genome sequencing of cohorts with structural birth defects and/or susceptibility to childhood cancer, with associated phenotypic and clinical data
- Knockout Mouse Phenotyping Program (KOMP2): Data from broad, standardized phenotyping of a genome-wide collection of mouse knockouts
- Library of Integrated Network-based Cellular Signatures: Molecular signatures that describe how different types of cells respond to a variety of agents that disrupt normal cellular function
- Metabolomics Workbench: Metabolomics data and metadata from studies on cells, tissues, and organisms
- Yes, there is no prohibition on the number of applications an institution may submit, provided the applications are scientifically distinct.
- Principal Investigators (PDs/PIs) of the Data Coordinating Centers (DCCs) for the participating Common Fund data sets listed above are not eligible to respond to this announcement.
- The Common Fund intends to commit approximately $2,000,000 in FY 2020. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Anticipated award amounts are for $200,000 in total costs, which is larger than typical R03 grants. More information on the R03 funding mechanism can be found at https://grants.nih.gov/grants/funding/r03.htm.
- The project period for an application submitted under this FOA is one year.
- If experimental approaches are proposed, they should not exceed 30% of the requested budget.
- Non-domestic entities and non-domestic components of U.S. organizations are not eligible to apply.
- Foreign components, as defined in the NIH Grants Policy State, are eligible to apply.
- Scientific and technical merit of the proposed project as determined by scientific peer review
- Availability of funds
- Relevance of the proposed project to program priorities
- Integration across multiple Common Fund data sets
This page last reviewed on November 12, 2019